Ann Fieuw

Safety, tolerability, pharmacokinetics, and pharmacodynamics of GLPG1690, a novel autotaxin inhibitor, to treat idiopathic pulmonary fibrosis (FLORA): a phase 2a randomised placebo-controlled trial

Toby M. Maher, Ellen M. van der Aar, Olivier Van de Steen et al. · The Lancet Respiratory Medicine · 2018 · 235 citations · Full text

Medicine, Pharmacokinetics, Pharmacology +7

Ziritaxestat, a Novel Autotaxin Inhibitor, and Lung Function in Idiopathic Pulmonary Fibrosis

Toby M. Maher, Paul Ford, Kevin M. Brown et al. · JAMA · 2023 · 127 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +10

Rationale, design and objectives of two phase III, randomised, placebo-controlled studies of GLPG1690, a novel autotaxin inhibitor, in idiopathic pulmonary fibrosis (ISABELA 1 and 2)

Toby M. Maher, Michael Kreuter, David J. Lederer et al. · BMJ Open Respiratory Research · 2019 · 101 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +13

Safety, Pharmacokinetics, and Pharmacodynamics of the Autotaxin Inhibitor GLPG1690 in Healthy Subjects: Phase 1 Randomized Trials

Ellen van der Aar, Julie Desrivot, Sonia Dupont et al. · The Journal of Clinical Pharmacology · 2019 · 42 citations · Full text

Pharmacy, Clinical Pharmacokinetics, Pharmacology +10

Safety, Pharmacokinetics, and Pharmacodynamics of the ADAMTS‐5 Inhibitor GLPG1972/S201086 in Healthy Volunteers and Participants With Osteoarthritis of the Knee or Hip

Ellen van der Aar, H. Deckx, Sonia Dupont et al. · Clinical Pharmacology in Drug Development · 2021 · 25 citations · Full text

Medicine, Pharmacokinetics, Pharmacology +8